Literature

Greulich et al., “A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: A feasibility randomized clinical trial,” Respir. Res., (2018)

Garn and Renz, “GATA-3-specific DNAzyme - A novel approach for stratified asthma therapy,” Eur. J. lmmunol., (2017)

Krug et al., “Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients,” J. Allergy Clin. lmmunol., (2017)

Popp et al., “Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice,” Gastroenterology, (2017)

Homburg et al. "Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma" J Allergy Clin Immunol. (2015): 797-800.

Krug et al. "Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme" New Engl J Med. (2015).

Fuhst et al. "Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure." Pulm Pharmacol Ther (2013).

Turowksa et al. " Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs." Toxicol Appl Pharmacol (2013).

Dicke et al. "Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes." Nucleic Acid Ther (2012).

Schmidts et al. " Development of drug delivery systems for the dermal application of therapeutic DNAzymes." Int J Pharm (2012).

Schmidts et al. " Protective effect of drug delivery systems against the enzymatic degradation of dermally applied DNAzyme." Int J Pharm 410 (2011): 75-82.

Schmidts et al. " Development of multiple W/O/W emulsions as dermal carrier system for oligonucleotides: effect of additives on emulsion stability." Int J Pharm 398 (2010): 107-113.

Sel et al. "Effective prevention and therapy of experimental asthma using a GATA-3 specific DNAzyme." JACI 121 (2008): 910-916.